Efficacy of Initial Basal-Supported Oral Therapy with Sitagliptin in Untreated Type 2 Diabetes
- Keiji Yoshioka
- … show all 1 hide
The present study assessed the efficacy of initial basal-supported oral therapy (BOT) with sitagliptin for achievement of glycemic control and subsequent switching from BOT to sitagliptin-based oral therapy.
Nineteen recently diagnosed type 2 diabetic patients who had received no antidiabetic medication in the previous 2 years were sequentially examined for the 24-week study. Patients were initially treated with a combination of insulin glargine and sitagliptin. Sitagliptin was initiated and maintained at a dose of 50 mg/day, and insulin glargine was started at a dose of 4 U at bedtime and adjusted if needed.
During the 24-week treatment period, 12 patients (63%) achieved HbA1c levels <7% (mean BOT duration 13.7 ± 5.6 weeks) and switched from BOT to sitagliptin monotherapy or in combination with metformin (achievers). The remaining seven patients (37%) failed to achieve HbA1c levels <7% (non-achievers) and continued on BOT. Both FPG and HbA1c in achievers significantly dropped at 4, 8, 12 and 24 weeks from baseline, while those in non-achievers significantly decreased at 12 and 24 weeks from baseline, but failed to reach target glycemic control. There were statistically significant differences in FPG at 4, 8, 12 and 24 weeks and in HbA1c at 8, 12 and 24 weeks between achievers and non-achievers. Body weight and BMI in achievers were significantly reduced at 12 and 24 weeks, but those in non-achievers did not change significantly. Dosage of concomitant insulin during BOT was significantly lower in achievers compared to non-achievers. Non-achievers had a similar CPI, a measure of insulin secretion capacity, to achievers, but significantly showed an insulin resistance index (value of 20/[fasting CPR × FPG]), in comparison to achievers.
Initiating BOT with sitagliptin followed by sitagliptin-based oral therapy is a useful option in untreated and poorly controlled patients with type 2 diabetes.
- Retnakaran R, Drucker DJ. Intensive insulin therapy in newly diagnosed type 2 diabetes. Lancet. 2008;371:1725–6. CrossRef
- Chen HS, Wu TE, Jap TS, et al. Beneficial effects of insulin on glycemic control and beta-cell function in newly diagnosed type 2 diabetes with severe hyperglycemia after short-term intensive insulin therapy. Diabetes Care. 2008;31:1927–32. CrossRef
- Shreiber RR, Ferlinz K, Haak T. The long-term efficacy of insulin glargine plus oral antidiabetic agents in a 32-month observational study of everyday clinical practice. Diabetes Technol Ther. 2008;10:121–7. CrossRef
- Kostev K, Dippel FW. Predictors for initiation of a basal supported oral therapy (BOT) in type 2 diabetic patients under real-life conditions in Germany. Prim Care Diabetes. 2012;6:329–35. CrossRef
- Ohtani T, Ito T. Safety and effectiveness of BOT (Basal supported Oral Therapy) using insulin glargine in Japanese patients with type 2 diabetes-results from postmarketing surveillance of insulin glargine (ALOHA study). Shinyaku to Rinsho (New Rem Clin). 2011;60:458–75 (in Japanese).
- Holman RR, Farmer AJ, Davies MJ, et al.; 4-T Study Group. Three-year efficacy of complex regimens in type 2 diabetes. N Engl J Med. 2009;361:1736–47.
- Sheen AJ. DDP-IV inhibitors in the management of type 2 diabetes: a critical review of head-to-head trials. Diabetes Metab. 2012;38:89–101. CrossRef
- Crepaldi G, Carruba M, Comaschi M, et al. Dipeptidyl peptidase 4 (DDP-4) inhibitors and their role in type 2 diabetes management. J Endocrinol Invest. 2007;30:610–4.
- Ahren B, Holst JJ, Martensson H, Balkan B. Improved glucose tolerance and insulin secretion by inhibition of dipeptidyl peptidase IV in mice. Eur J Pharmacol. 2000;404:239–45. CrossRef
- Seino Y, Fukushima M, Yabe D. GIP and GLP-1, two incretin hormones: similarities and differences. J Diabetes Invest. 2010;1:8–23. CrossRef
- Iwamoto Y, Kashiwagi A, Yamada N, et al. Efficacy and safety of vildagliptin and voglibose in Japanese patients with type 2 diabetes: a 12-week, randomized, double-blind, active controlled study. Diabetes Obes Metab. 2010;12:700–8. CrossRef
- Sakamoto M, Nishimura R, Irako T, et al. Comparison of vildagliptin vs. sitagliptin one daily using continuous glucose monitoring (CGM): crossover pilot study (J-VICTORIA study). Cardiovasc Diabetol. 2012;11:92–8. CrossRef
- Yoshioka K, Isotani H, Ohashi S, Imamura M. Efficacy of vildagliptin on glucose fluctuation in Japanese type 2 diabetic patients with ongoing sulfonylurea based oral glycemic agent therapy. Diabetes Metab Syndr. 2013;7:32–4. CrossRef
- Vilsbøll T, Rosebstock J, Yki-Järvinen H, et al. Efficacy and safety of sitagliptin when added to insulin therapy in patients with type 2 diabetes. Diabetes Obes Metab. 2010;12:167–77. CrossRef
- Fonseca V, Schweizer A, Albrecht D, et al. Addition of vildagliptin to insulin improves glycemic control in type 2 diabetes. Diabetologia. 2007;50:1148–55. CrossRef
- Katsuno T, Ikeda H, Ida K, Miyagawa J, Namba M. Add-on therapy with the DPP-4 inhibitor sitagliptin improves glycemic control in insulin-treated Japanese patients with type 2 diabetes mellitus. Endocr J. 2013;60:733–42. CrossRef
- Japan Diabetes Society. Dietary and exercise therapy. In: Treatment guide for diabetes 2012. Tokyo: Bunkodo Co., Ltd. 2012;39–45 (in Japanese).
- Funakoshi S, Fujimoto S, Hamasaki A, et al. Analysis of factors influencing pancreatic beta-cell function in Japanese patients with type 2 diabetes. Association with body mass index and duration of diabetic exposure. Diabetes Res Clin Pract. 2008;82:353–8. CrossRef
- Ohkura T, Shiochi H, Fujioka Y, et al. 20/(fasting C-peptide × fasting plasma glucose) is a simple and effective index of insulin resistance in patients with type 2 diabetes mellitus: a preliminary report. Cardiovasc Diabetol. 2013;12:21–8. CrossRef
- Kadowaki T, Ohtani T, Odawara M. Baseline predictive factors for glycemic control in Japanese type 2 diabetes patients treated with insulin glargine plus oral antidiabetic drugs: ALOHA study subanalysis. Diabetol Int. 2013;4:16–22. CrossRef
- Harashima SI, Tanaka D, Yamane S, et al. Efficacy and safety of switching from basal insulin to sitagliptin in Japanese type 2 diabetes patients. Horm Metab Res. 2013;45:231–8.
- Efficacy of Initial Basal-Supported Oral Therapy with Sitagliptin in Untreated Type 2 Diabetes
- Open Access
- Available under Open Access This content is freely available online to anyone, anywhere at any time.
Volume 4, Issue 2 , pp 409-416
- Cover Date
- Print ISSN
- Online ISSN
- Springer Healthcare
- Additional Links
- Basal-supported oral therapy (BOT)
- Type 2 diabetes
- Industry Sectors
- Keiji Yoshioka (1)
- Author Affiliations
- 1. Yoshioka Diabetes Clinic, 4F, The Tower, Bunroku Hills, Moriguchi Midsite, 11-2, Moriguchi, Osaka, 570-0028, Japan